Anti-Cancer Agents in Medicinal Chemistry

(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Michelle Prudhomme  
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex


Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors

Author(s): Fatih M. Uckun, Alexei Vassilev, Ilker Dibirdik, Heather Tibbles.


Inhibitors of Janus Kinase 3 (JAK3) show potential as a new class of apoptosis-inducing anti-cancer drugs. In addition, JAK3 inhibitors may also be useful as immunosuppressive agents. Rationally designed selective inhibitors of JAK3 such as JANEX-1, that do not inhibit other Janus kinases have recently undergone extensive preclinical testing that revealed a favorable pharmacodynamic profile. Here we discuss the clinical potential of targeting JAK3-linked signal transduction pathways with small molecule inhibitors such as JANEX-1.

Keywords: Rational Drug Design, Tyrosine Kinases, Inhibitors, JAK3

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2007
Page: [612 - 623]
Pages: 12
DOI: 10.2174/187152007784111304
Price: $58